Bivatuzumab

(Synonyms: BIWA 4; Anti-CD44 Recombinant Antibody)
Customer Review

Based on 1 Customer Validation

Bivatuzumab (BIWA 4) is a humanized monoclonal antibody targeting CD44v6. Bivatuzumab binds the v6 variant exon of CD44 with a Kd of 3.4 nM, undergoes internalization after binding, and achieves tumor localization. Bivatuzumab is inactive in antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. Bivatuzumab can serve as the antibody component for synthesizing antibody-drug conjugates (ADCs), such as Bivatuzumab mertansine (BIWI 1). Bivatuzumab can be used for research on head and neck squamous cell carcinoma or esophageal squamous cell carcinoma.

For research use only. We do not sell to patients.

  • Purity : 99.82%
  • CAS No.: 214559-60-1
  • Molecular Weight:143.22 kDa
  • Storage:
    Shipping with dry ice

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Biological Activity
  • Chemical Information
  • Protocols
  • Purity & Documentation
  • References
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00